Fairmount Funds Management LLC bought $10.0M of Viridian Therapeutics (VRDN)
Executed Oct 23 2025, disclosed Oct 27 2025, 4 days later.
Over the 21 trading sessions from the disclosed entry session (Oct 27 2025), the stock returned +42.7% (delay-adjusted); from the execution session (Oct 23 2025), +34.6%. Derived: entry at the session's open, exit at the close 20 sessions later.
Fairmount Funds Management LLC (Director) filed 8 Form 4 reports as a reporting entity in the trailing twelve months (4 purchases, 4 sales), most often in Cogent Biosciences, Inc. (COGT). Across 4 priced purchase filings, the average 21-session return was -7.3% from execution and -3.8% from disclosure (delay-adjusted; derived). The largest single filing was $399.7M of SYRE (4,684,781 sh × $85.31, as filed), executed Jun 23.
Healthcare · Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→1,176,470 sh × $17.00
Exec May 11
Filed May 13 · 4:31 PM ET